vs
Eos Energy Enterprises, Inc.（EOSE）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Eos Energy Enterprises, Inc.的季度营收约是REGENXBIO Inc.的1.9倍（$58.0M vs $30.3M），Eos Energy Enterprises, Inc.净利率更高（-207.7% vs -221.3%，领先13.7%），Eos Energy Enterprises, Inc.同比增速更快（699.6% vs 43.0%），REGENXBIO Inc.自由现金流更多（$-52.8M vs $-75.2M）
Eos Energy Enterprises是一家专注于锌基长时储能电池技术研发、生产与商业化部署的企业，为公用事业、工商业、微电网等客户提供安全环保的储能解决方案，服务覆盖多区域市场，助力可再生能源消纳与电网稳定运行。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
EOSE vs RGNX — 直观对比
营收规模更大
EOSE
是对方的1.9倍
$30.3M
营收增速更快
EOSE
高出656.6%
43.0%
净利率更高
EOSE
高出13.7%
-221.3%
自由现金流更多
RGNX
多$22.4M
$-75.2M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $58.0M | $30.3M |
| 净利润 | $-120.5M | $-67.1M |
| 毛利率 | -93.8% | — |
| 营业利润率 | -140.1% | -190.0% |
| 净利率 | -207.7% | -221.3% |
| 营收同比 | 699.6% | 43.0% |
| 净利润同比 | 55.1% | -31.2% |
| 每股收益（稀释后） | $-0.53 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EOSERGNX
| Q4 25 | $58.0M | $30.3M | ||
| Q3 25 | $30.5M | $29.7M | ||
| Q2 25 | $15.2M | $21.4M | ||
| Q1 25 | $10.5M | $89.0M | ||
| Q4 24 | $7.3M | $21.2M | ||
| Q3 24 | — | $24.2M | ||
| Q2 24 | — | $22.3M | ||
| Q1 24 | — | $15.6M |
净利润EOSERGNX
| Q4 25 | $-120.5M | $-67.1M | ||
| Q3 25 | $-641.4M | $-61.9M | ||
| Q2 25 | $-222.9M | $-70.9M | ||
| Q1 25 | $15.1M | $6.1M | ||
| Q4 24 | $-268.1M | $-51.2M | ||
| Q3 24 | — | $-59.6M | ||
| Q2 24 | — | $-53.0M | ||
| Q1 24 | — | $-63.3M |
毛利率EOSERGNX
| Q4 25 | -93.8% | — | ||
| Q3 25 | -111.2% | — | ||
| Q2 25 | -203.2% | — | ||
| Q1 25 | -234.7% | — | ||
| Q4 24 | -324.0% | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率EOSERGNX
| Q4 25 | -140.1% | -190.0% | ||
| Q3 25 | -200.6% | -176.3% | ||
| Q2 25 | -419.1% | -296.3% | ||
| Q1 25 | -506.2% | 13.6% | ||
| Q4 24 | -712.8% | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | — | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率EOSERGNX
| Q4 25 | -207.7% | -221.3% | ||
| Q3 25 | -2102.1% | -208.3% | ||
| Q2 25 | -1463.2% | -331.8% | ||
| Q1 25 | 144.7% | 6.8% | ||
| Q4 24 | -3696.7% | -241.3% | ||
| Q3 24 | — | -246.3% | ||
| Q2 24 | — | -237.7% | ||
| Q1 24 | — | -405.4% |
每股收益（稀释后）EOSERGNX
| Q4 25 | $-0.53 | $-1.30 | ||
| Q3 25 | $-4.91 | $-1.20 | ||
| Q2 25 | $-1.05 | $-1.38 | ||
| Q1 25 | $-0.20 | $0.12 | ||
| Q4 24 | $-2.30 | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $568.0M | $230.1M |
| 总债务越低越好 | $813.3M | — |
| 股东权益账面价值 | $-2.2B | $102.7M |
| 总资产 | $885.2M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EOSERGNX
| Q4 25 | $568.0M | $230.1M | ||
| Q3 25 | $58.7M | $274.2M | ||
| Q2 25 | $120.2M | $323.3M | ||
| Q1 25 | $82.6M | $267.9M | ||
| Q4 24 | $74.3M | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务EOSERGNX
| Q4 25 | $813.3M | — | ||
| Q3 25 | $448.5M | — | ||
| Q2 25 | $445.3M | — | ||
| Q1 25 | $325.5M | — | ||
| Q4 24 | $316.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EOSERGNX
| Q4 25 | $-2.2B | $102.7M | ||
| Q3 25 | $-2.3B | $161.5M | ||
| Q2 25 | $-1.1B | $213.7M | ||
| Q1 25 | $-942.2M | $274.2M | ||
| Q4 24 | $-1.1B | $259.7M | ||
| Q3 24 | — | $301.4M | ||
| Q2 24 | — | $348.3M | ||
| Q1 24 | — | $390.7M |
总资产EOSERGNX
| Q4 25 | $885.2M | $453.0M | ||
| Q3 25 | $328.2M | $525.2M | ||
| Q2 25 | $361.0M | $581.0M | ||
| Q1 25 | $263.3M | $490.9M | ||
| Q4 24 | $260.3M | $466.0M | ||
| Q3 24 | — | $519.1M | ||
| Q2 24 | — | $569.4M | ||
| Q1 24 | — | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-50.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-75.2M | $-52.8M |
| 自由现金流率自由现金流/营收 | -129.7% | -174.0% |
| 资本支出强度资本支出/营收 | 43.1% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-265.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流EOSERGNX
| Q4 25 | $-50.3M | $-52.3M | ||
| Q3 25 | $-65.9M | $-56.0M | ||
| Q2 25 | $-66.1M | $-49.3M | ||
| Q1 25 | $-28.9M | $33.6M | ||
| Q4 24 | $-42.7M | $-31.6M | ||
| Q3 24 | — | $-40.5M | ||
| Q2 24 | — | $-45.5M | ||
| Q1 24 | — | $-55.5M |
自由现金流EOSERGNX
| Q4 25 | $-75.2M | $-52.8M | ||
| Q3 25 | $-82.7M | $-56.5M | ||
| Q2 25 | $-73.2M | $-49.7M | ||
| Q1 25 | $-33.8M | $32.6M | ||
| Q4 24 | $-55.8M | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率EOSERGNX
| Q4 25 | -129.7% | -174.0% | ||
| Q3 25 | -271.1% | -189.9% | ||
| Q2 25 | -480.2% | -232.8% | ||
| Q1 25 | -323.6% | 36.6% | ||
| Q4 24 | -769.1% | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度EOSERGNX
| Q4 25 | 43.1% | 1.7% | ||
| Q3 25 | 55.2% | 1.7% | ||
| Q2 25 | 46.2% | 1.8% | ||
| Q1 25 | 47.0% | 1.2% | ||
| Q4 24 | 180.6% | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率EOSERGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -1.91× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EOSE
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
